and PLC-PRF-5 hepatocellular carcinoma cells; MCF-7, MDA-MB-231, MDA-MB-468,
SKBR3, and ZR-75 breast cancer cells; and normal-like epithelial MCF-10A
breast cells were cultured in low-glucose Dulbecco’s modified
Eagle’s medium (DMEM) (Biological Industries-BI) supplemented
with 10% fetal bovine serum (FBS) (Gibco/Thermo Fisher Scientific),
2 mM
Penicillin/Streptomycin, and 0.1 mM non-essential
amino acid (Gibco/Thermo Fisher Scientific). SNU475 hepatocellular
carcinoma cells were maintained in RPMI (Biological Industries-BI)
supplemented with 10% fetal bovine serum (FBS) (Gibco/Thermo Fisher
Scientific),
and 100 Units/mL Penicillin/Streptomycin, while ZR-75 breast cancer
cells were cultured RPMI (Biological Industries-BI) supplemented with
10% fetal bovine serum (FBS) (Gibco/Thermo Fisher Scientific), 1×
sodium pyruvate, and %4.5 glucose. Normal-like MCF-10A breast cells
were sustained in DMEM/HAM’S F12 (Hyclone) supplemented with
10% fetal bovine serum (FBS) (Gibco/Thermo Fisher Scientific), EGF
(20 ng/mL), Hydrocortisone (0.5 mg/mL), cholera toxin (100 ng/mL),
insulin (10 μg/mL), and 100 Units/mL Penicillin/Streptomycin.
The cells were cultivated at 37 °C in a humidified incubator
under 5% CO2.